Silence Therapeutics (NASDAQ:SLN) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.21) by 47.62 percent. This is a 45 percent increase over losses of $(0.20) per share from the same period last year. The company reported quarterly sales of $422.000 thousand which missed the analyst consensus estimate of $2.439 million by 82.70 percent. This is a 197.18 percent increase over sales of $142.000 thousand the same period last year.